Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant

Cristina Papayannidis, Chiara Sartor, Alida Dominietto, Elisabetta Zappone, Mario Arpinati, Giovanni Marconi, Gianluca Cristiano, Jacopo Nanni, Sarah Parisi, Francesco Barbato, Stefania Paolini, Simona Soverini, Carolina Terragna, Valentina Robustelli, Nicoletta Testoni, Gabriella Chirumbolo, Antonio Curti, Michele Cavo, Francesca Bonifazi

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)580-583
Number of pages4
JournalHematological Oncology
Issue number4
Publication statusPublished - Oct 2021


  • Adolescent
  • Adult
  • Antineoplastic Agents, Immunological/therapeutic use
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Inotuzumab Ozogamicin/therapeutic use
  • Lymphocyte Transfusion/methods
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local/pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology
  • Prognosis
  • Retrospective Studies
  • Salvage Therapy
  • Stem Cell Transplantation/methods
  • Survival Rate
  • Young Adult

Cite this